A total of 94 institutions have reported a stake in Design Therapeutics, Inc. (NASDAQ:DSGN) as of September 2025, according to recent 13F filings with the SEC.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 30 Sep, 2025 | 6,526,476 | 0 | 0.00% | $49,144,364.00 |
| Logos Global Management LP | 30 Sep, 2025 | 3,655,000 | -562,627 | -13.34% | $27,522,150.00 |
| Point72 Asset Management, L.P. | 30 Sep, 2025 | 3,340,552 | 1,533,334 | 84.84% | $25,154,353.00 |
| Almitas Capital LLC | 30 Sep, 2025 | 3,060,870 | 1,530,435 | 100.00% | $23,048,352.00 |
| BlackRock, Inc. | 30 Sep, 2025 | 2,044,388 | -351,355 | -14.67% | $15,394,241.00 |
| Frazier Life Sciences Management, L.P. | 30 Sep, 2025 | 1,953,547 | 0 | 0.00% | $14,710,209.00 |
| TANG CAPITAL MANAGEMENT LLC | 30 Sep, 2025 | 1,780,975 | 0 | 0.00% | $13,410,742.00 |
| BAKER BROS. ADVISORS LP | 30 Sep, 2025 | 1,712,882 | 0 | 0.00% | $12,898,001.00 |
| VANGUARD GROUP INC | 30 Sep, 2025 | 1,443,701 | -27,873 | -1.89% | $10,871,069.00 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 30 Sep, 2025 | 1,076,236 | 0 | 0.00% | $8,104,057.00 |
| Kynam Capital Management, LP | 30 Sep, 2025 | 1,029,579 | 0 | 0.00% | $7,752,730.00 |
| FMR LLC | 30 Sep, 2025 | 740,849 | -210,349 | -22.11% | $5,578,593.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 30 Sep, 2025 | 695,613 | -98,395 | -12.39% | $5,239,165.00 |
| STATE STREET CORP | 30 Sep, 2025 | 634,397 | -84,815 | -11.79% | $4,777,009.00 |
| ACADIAN ASSET MANAGEMENT LLC | 30 Sep, 2025 | 617,489 | -9,859 | -1.57% | $4,648.00 |
| Woodline Partners LP | 30 Sep, 2025 | 612,712 | -164,825 | -21.20% | $4,613,721.00 |
| MPM BioImpact LLC | 30 Sep, 2025 | 555,187 | 0 | 0.00% | $4,180,558.00 |
| CITADEL ADVISORS LLC | 30 Sep, 2025 | 554,020 | -409,440 | -42.50% | $4,171,771.00 |
| RA CAPITAL MANAGEMENT, L.P. | 30 Sep, 2025 | 475,699 | -2,495,532 | -83.99% | $3,582,013.00 |
| D. E. Shaw & Co., Inc. | 30 Sep, 2025 | 373,276 | -17,372 | -4.45% | $2,810,768.00 |